Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

iCAD's AI shows promise in breast cancer detection

EditorNatashya Angelica
Published 02/28/2024, 01:49 PM
Updated 02/28/2024, 01:49 PM
© Reuters.

NASHUA, N.H. - iCAD, Inc. (NASDAQ: NASDAQ:ICAD), a company specializing in AI-powered cancer detection solutions, presented new clinical data at the European Congress of Radiology (ECR) annual meeting in Vienna, which took place from February 28 to March 3, 2024. The data suggest that iCAD's ProFound Detection AI may help reduce breast interval cancer rates and decrease recall rates without increasing false negatives.

A study from the Reggio Emilia Breast Screening Program in Italy, using iCAD's ProFound AI 2D system, indicated that the integration of the company's AI mammography case malignancy scoring could reduce radiologists' workload by up to 30.6%.

This reduction was achieved without compromising diagnostic accuracy, as the study found a modest improvement in recall rate and no increase in false negatives.

Another study, involving 151,245 screening mammograms, examined whether ProFound AI could reduce the occurrence of interval carcinomas, which are cancers detected between regular screening appointments. The software is expected to enhance detection rates and is suggested to potentially outperform radiologists in identifying these cancers.

Additionally, the AI was shown to expedite the diagnostic process for likely true positive cases, complying with regulations requiring readings within two weeks. A retrospective analysis demonstrated that prioritizing exams with higher AI-generated case scores could identify the majority of screen-detected cancers while significantly reducing the number of exams that required reading.

The conference also featured a poster presentation that won the Certificate of Merit award, showcasing the potential of using Breast Arterial Calcification (BAC) detected by ProFound AI Heart Health as a biomarker for evaluating cardiovascular disease in women.

3rd party Ad. Not an offer or recommendation by See disclosure here or remove ads .

A score of 3 or higher was linked to a higher rate of significant atherosclerotic disease, suggesting BAC assessment could be instrumental in identifying individuals for further cardiovascular screening.

iCAD's latest enhancements to its ProFound Detection solution aim to improve readability for radiologists by limiting lesion marks and introducing a color-coded scorecard. These updates, along with expanded cloud platform and subscription licensing plans, are part of iCAD's strategy to provide ongoing software improvements and support.

This information is based on a press release statement from iCAD, Inc. The company continues to focus on providing AI-powered solutions for early cancer detection and improving patient outcomes.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.